Intravitreal Anti-Vegf Agents, Oral Glucocorticoids, And Laser Photocoagulation Combination Therapy For Macular Edema Secondary To Retinal Vein Occlusion: Preliminary Report

Xiao-Xiao Feng,Cheng Li,Wan-Wen Shao,Yong-Guang Yuan,Xiao-Bing Qian,Qi-Shan Zheng,Yu-Jie Li,Qian-Ying Gao
DOI: https://doi.org/10.18240/ijo.2018.03.13
IF: 1.645
2018-01-01
International Journal of Ophthalmology
Abstract:AIM: To evaluate the efficacy and safety of combined anti-vascular endothelial growth factor (VEGF) agents, oral glucocorticoid, and laser photocoagulation therapy for macular edema (ME) secondary to retinal vein occlusion (RVO).METHODS: This study included 16 eyes of 16 patients with RVO-associated ME. Patients were initially treated with oral prednisone and an intravitreal anti-VEGF agent. Two weeks later, patients underwent standard laser photocoagulation. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and retinal vessel oxygenation were examined over 12mo.RESULTS: Patients received 1.43 +/- 0.81 anti-VEGF injections. Mean baseline and 12-month logMAR BCVA were 0.96 +/- 0.51 (20/178) and 0.31 +/- 0.88 (20/40), respectively, in eyes with central retinal vein occlusion (CRVO) (P<0.00), and 1.02 +/- 0.45 (20/209) and 0.60 +/- 0.49 (20/80), respectively, in eyes with branch retinal vein occlusion (BRVO) (P<0.00). At 12mo, CRT had significantly decreased in eyes with CRVO (P<0.00) and BRVO (P<0.00). Venous oxygen saturation had significantly increased in eyes with CRVO (P<0.00) and BRVO (P<0.00). No examined parameters were significantly different between the 2 RVO groups. No serious adverse effects occurred.CONCLUSION: Anti-VEGF, glucocorticoid, and photocoagulation combination therapy improves visual outcome, prolongs therapeutic effect, and reduces the number of intravitreal injections in eyes with RVO-associated ME.
What problem does this paper attempt to address?